A Significant Breakthrough in Oncology Recent clinical trial results have brought a wave of optimism for patients battling advanced gastric and gastroesophageal junction (GEJ) cancers. The antibody-drug conjugate sonesitatug vedotin has demonstrated a remarkable ability to improve survival outcomes in patients who have exhausted earlier lines of treatment. Understanding the Study Results The clinical trial…